Literature DB >> 20523247

Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.

Javier Márquez-Rivas1, Gema Ramirez, Angela Ollero-Ortiz, Jorge Giménez-Pando, Juan Emmerich, Eduardo Quiroga-Cantero, Eloy Rivas, Emilio Gómez-González.   

Abstract

BACKGROUND: Glioblastomas occur infrequently in children, and the prognosis is better than for glioblastomas seen in adults. Aggressive treatment is justified in pediatric patients. OBSERVATIONS: We present the case of a 6-year-old child with malignant posterior temporal glioma treated with surgery, radiotherapy, local chemotherapy with carmustine wafers, and oral therapy with temozolomide, both at initial diagnosis and at relapse 18 months later. After 6 years, the patient seems healthy with no focal neurologic signs, and imaging studies show no evidence of disease.
CONCLUSION: Multimodal therapy was found to have a very positive outcome for a child with malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20523247     DOI: 10.1097/MPH.0b013e3181e0d16b

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Treatment of glioblastoma multiforme with high doses of carmustine intracavitary, in an infant.

Authors:  Mónica Rivero-Garvía; J Márquez-Rivas; A B Rueda-Torres; D Pascual-Argente; G Ramírez
Journal:  Childs Nerv Syst       Date:  2011-12-29       Impact factor: 1.475

2.  In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.

Authors:  Susanna J E Veringa; Dennis Biesmans; Dannis G van Vuurden; Marc H A Jansen; Laurine E Wedekind; Ilona Horsman; Pieter Wesseling; William Peter Vandertop; David P Noske; GertJan J L Kaspers; Esther Hulleman
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.